Literature DB >> 33820995

Integrative microbiomics in bronchiectasis exacerbations.

Micheál Mac Aogáin1, Jayanth Kumar Narayana1, Pei Yee Tiew1,2, Nur A'tikah Binte Mohamed Ali1, Valerie Fei Lee Yong1, Tavleen Kaur Jaggi1, Albert Yick Hou Lim3, Holly R Keir4, Alison J Dicker4, Kai Xian Thng1, Akina Tsang1, Fransiskus Xaverius Ivan1, Mau Ern Poh5, Martina Oriano6,7, Stefano Aliberti6,7, Francesco Blasi6,7, Teck Boon Low8, Thun How Ong2, Brian Oliver9,10, Yan Hui Giam4, Augustine Tee8, Mariko Siyue Koh2, John Arputhan Abisheganaden3, Krasimira Tsaneva-Atanasova11, James D Chalmers4, Sanjay H Chotirmall12.   

Abstract

Bronchiectasis, a progressive chronic airway disease, is characterized by microbial colonization and infection. We present an approach to the multi-biome that integrates bacterial, viral and fungal communities in bronchiectasis through weighted similarity network fusion ( https://integrative-microbiomics.ntu.edu.sg ). Patients at greatest risk of exacerbation have less complex microbial co-occurrence networks, reduced diversity and a higher degree of antagonistic interactions in their airway microbiome. Furthermore, longitudinal interactome dynamics reveals microbial antagonism during exacerbation, which resolves following treatment in an otherwise stable multi-biome. Assessment of the Pseudomonas interactome shows that interaction networks, rather than abundance alone, are associated with exacerbation risk, and that incorporation of microbial interaction data improves clinical prediction models. Shotgun metagenomic sequencing of an independent cohort validated the multi-biome interactions detected in targeted analysis and confirmed the association with exacerbation. Integrative microbiomics captures microbial interactions to determine exacerbation risk, which cannot be appreciated by the study of a single microbial group. Antibiotic strategies probably target the interaction networks rather than individual microbes, providing a fresh approach to the understanding of respiratory infection.

Entities:  

Year:  2021        PMID: 33820995     DOI: 10.1038/s41591-021-01289-7

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  66 in total

Review 1.  Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity.

Authors:  Patrick A Flume; James D Chalmers; Kenneth N Olivier
Journal:  Lancet       Date:  2018-09-08       Impact factor: 79.321

2.  Time to acknowledge, address, and take action against bronchiectasis.

Authors:  Sanjay H Chotirmall; Pamela J McShane
Journal:  Lancet Glob Health       Date:  2019-09       Impact factor: 26.763

3.  The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial.

Authors:  Geraint B Rogers; Kenneth D Bruce; Megan L Martin; Lucy D Burr; David J Serisier
Journal:  Lancet Respir Med       Date:  2014-10-14       Impact factor: 30.700

Review 4.  Bronchiectasis.

Authors:  James D Chalmers; Anne B Chang; Sanjay H Chotirmall; Raja Dhar; Pamela J McShane
Journal:  Nat Rev Dis Primers       Date:  2018-11-15       Impact factor: 52.329

5.  A novel microbiota stratification system predicts future exacerbations in bronchiectasis.

Authors:  Geraint B Rogers; Nur Masirah M Zain; Kenneth D Bruce; Lucy D Burr; Alice C Chen; Damian W Rivett; Michael A McGuckin; David J Serisier
Journal:  Ann Am Thorac Soc       Date:  2014-05

6.  Characterization of the "Frequent Exacerbator Phenotype" in Bronchiectasis.

Authors:  James D Chalmers; Stefano Aliberti; Anna Filonenko; Michal Shteinberg; Pieter C Goeminne; Adam T Hill; Thomas C Fardon; Dusanka Obradovic; Christoph Gerlinger; Giovanni Sotgiu; Elisabeth Operschall; Robert M Rutherford; Katerina Dimakou; Eva Polverino; Anthony De Soyza; Melissa J McDonnell
Journal:  Am J Respir Crit Care Med       Date:  2018-06-01       Impact factor: 21.405

7.  Longitudinal assessment of sputum microbiome by sequencing of the 16S rRNA gene in non-cystic fibrosis bronchiectasis patients.

Authors:  Michael J Cox; Elena M Turek; Catherine Hennessy; Ghazala K Mirza; Phillip L James; Meg Coleman; Andrew Jones; Robert Wilson; Diana Bilton; William O C Cookson; Miriam F Moffatt; Michael R Loebinger
Journal:  PLoS One       Date:  2017-02-07       Impact factor: 3.240

8.  Viruses in bronchiectasis: a pilot study to explore the presence of community acquired respiratory viruses in stable patients and during acute exacerbations.

Authors:  Alicia B Mitchell; Bassel Mourad; Lachlan Buddle; Matthew J Peters; Brian G G Oliver; Lucy C Morgan
Journal:  BMC Pulm Med       Date:  2018-05-22       Impact factor: 3.317

9.  Immunological corollary of the pulmonary mycobiome in bronchiectasis: the CAMEB study.

Authors:  Micheál Mac Aogáin; Ravishankar Chandrasekaran; Albert Yick Hou Lim; Teck Boon Low; Gan Liang Tan; Tidi Hassan; Thun How Ong; Amanda Hui Qi Ng; Denis Bertrand; Jia Yu Koh; Sze Lei Pang; Zi Yang Lee; Xiao Wei Gwee; Christopher Martinus; Yang Yie Sio; Sri Anusha Matta; Fook Tim Chew; Holly R Keir; John E Connolly; John Arputhan Abisheganaden; Mariko Siyue Koh; Niranjan Nagarajan; James D Chalmers; Sanjay H Chotirmall
Journal:  Eur Respir J       Date:  2018-07-27       Impact factor: 16.671

10.  A longitudinal characterization of the Non-Cystic Fibrosis Bronchiectasis airway microbiome.

Authors:  T E Woo; R Lim; A A Heirali; N Acosta; H R Rabin; C H Mody; R Somayaji; M G Surette; C D Sibley; D G Storey; M D Parkins
Journal:  Sci Rep       Date:  2019-05-03       Impact factor: 4.379

View more
  17 in total

1.  Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis.

Authors:  Miguel Ángel Martínez-García; Grace Oscullo; Alberto García-Ortega; Maria Gabriella Matera; Paola Rogliani; Mario Cazzola
Journal:  Drugs       Date:  2021-11-26       Impact factor: 9.546

Review 2.  Lung microbial-host interface through the lens of multi-omics.

Authors:  Shivani Singh; Jake G Natalini; Leopoldo N Segal
Journal:  Mucosal Immunol       Date:  2022-07-06       Impact factor: 8.701

Review 3.  Advances in diagnostic tools for respiratory tract infections: from tuberculosis to COVID-19 - changing paradigms?

Authors:  Zoran Stojanovic; Filipe Gonçalves-Carvalho; Alicia Marín; Jorge Abad Capa; Jose Domínguez; Irene Latorre; Alicia Lacoma; Cristina Prat-Aymerich
Journal:  ERJ Open Res       Date:  2022-09-12

Review 4.  ERS International Congress 2021: highlights from the Respiratory Infections Assembly.

Authors:  Oliver W Meldrum; Kylie B R Belchamber; Kiarina D Chichirelo-Konstantynovych; Katie L Horton; Tetyana V Konstantynovych; Merete B Long; Melissa J McDonnell; Lidia Perea; Alberto L Garcia-Basteiro; Michael R Loebinger; Raquel Duarte; Holly R Keir
Journal:  ERJ Open Res       Date:  2022-05-23

Review 5.  Clinical Aspergillus Signatures in COPD and Bronchiectasis.

Authors:  Pei Yee Tiew; Kai Xian Thng; Sanjay H Chotirmall
Journal:  J Fungi (Basel)       Date:  2022-05-05

6.  Testing Two Somatic Cell Count Cutoff Values for Bovine Subclinical Mastitis Detection Based on Milk Microbiota and Peripheral Blood Leukocyte Transcriptome Profile.

Authors:  Jinning Zhang; Wenlong Li; Yongjie Tang; Xueqin Liu; Hailiang Zhang; Yueling Zhou; Yachun Wang; Wei Xiao; Ying Yu
Journal:  Animals (Basel)       Date:  2022-06-30       Impact factor: 3.231

Review 7.  Inhaled Corticosteroids in Adults with Non-cystic Fibrosis Bronchiectasis: From Bench to Bedside. A Narrative Review.

Authors:  Miguel Ángel Martínez-García; Mario Cazzola; Grace Oscullo; Alberto García-Ortega; Maria Gabriella Matera; Paola Rogliani
Journal:  Drugs       Date:  2022-10-20       Impact factor: 11.431

Review 8.  Precision medicine in bronchiectasis.

Authors:  Thomas Pembridge; James D Chalmers
Journal:  Breathe (Sheff)       Date:  2021-12

Review 9.  Protease-Antiprotease Imbalance in Bronchiectasis.

Authors:  Martina Oriano; Francesco Amati; Andrea Gramegna; Anthony De Soyza; Marco Mantero; Oriol Sibila; Sanjay H Chotirmall; Antonio Voza; Paola Marchisio; Francesco Blasi; Stefano Aliberti
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

Review 10.  Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases.

Authors:  Francesco Amati; Anna Stainer; Marco Mantero; Andrea Gramegna; Edoardo Simonetta; Giulia Suigo; Antonio Voza; Anoop M Nambiar; Umberto Cariboni; Justin Oldham; Philip L Molyneaux; Paolo Spagnolo; Francesco Blasi; Stefano Aliberti
Journal:  Int J Mol Sci       Date:  2022-01-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.